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of phosphorylated tau (Delacourte et al., 1999). In addition, an inverse 
relationship has been found in damaged regions between the number 
of extracellular NFT ghost tangles and the number of surviving cells 
(Bondareff et al., 1989; Cras et al., 1995). This observation suggests 
that neurons containing NFT could degenerate and release their 
intracellular NFT into the extracellular environment (Gomez-Ramos 
et al., 2006), which may then be toxic for the surrounding neurons 
(Gomez-Ramos et al., 2006, 2008). Indeed, all cytoplasmic proteins 
are released into the extracellular space after neuron death and some 
of these proteins could be toxic in this milieu. We hypothesized that 
it is extracellular tau that is indeed toxic to neurons (Gomez-Ramos 
et al., 2006) and in this short review, I will describe some of the studies 
that have been carried out to test this hypothesis. However, in testing 
this hypothesis, we must take care to distinguish between the possible 
toxic role for intracellular tau and that of extracellular tau.
Intracellular tau
It has been suggested that as well as an increase in the amount 
of tau (Andorfer et al., 2005), structural changes to this protein, 
modifications by phosphorylation, or its aggregation could pro-
duce toxic effects in cells (Avila et al., 2004; Duff and Planel, 2005; 
Bretteville and Planel, 2008; Takashima, 2008). An excess of tau 
protein could inhibit the trafficking of vesicles and organelles in 
neurons (Stamer et al., 2002). Indeed, an increase in the amount of 
tau protein could impair microtubule dependent axonal transport 
(Dixit et al., 2008), although this remains to be confirmed (Yuan 
et al., 2008). Nevertheless, reducing the amount of endogenous tau 
ameliorates amyloid-beta toxicity (Rapoport et al., 2002; Roberson 
et al., 2007) and tau suppression in a mouse model improves mem-
ory function (Santacruz et al., 2005).
IntroductIon
The tau protein was initially identified from isolated brain micro-
tubules as a microtubule-associated protein (MAP) (Weingarten 
et al., 1975). Subsequent in vitro analyses and studies in cultured 
cells then suggested that the tau protein facilitates in microtubule 
assembly and the stabilization of microtubule polymers (Cleveland 
et al., 1977; Drubin and Kirschner, 1986; Caceres and Kosik, 1990), 
indicating that tau could suppress microtubule dynamics (Panda 
et al., 1995). This function could also be performed by other MAPs, 
which would explain the viability of tau-deficient mice produced by 
gene targeting (Harada et al., 1994; Dawson et al., 2001), although 
some differences have been identified with respect to the wild-type 
mouse (see below).
It has been suggested that alterations in the amount or con-
formation of tau, as well as other modifications to this protein 
could have pathological effects. This modifications provoke disor-
ders known as tauopathies (Hernandez and Avila, 2007), of which 
Alzheimer’s disease (AD) is the most prevalent. Tauopathies are 
neurodegenerative disease in which neurodegeneration is associ-
ated with the presence of phosphorylated or/and aggregated tau 
(Hernandez and Avila, 2007).
Alzheimer’s disease is characterized by the presence of two specific 
structures in the brain of patients, senile plaques (SP), and neu-
rofibrillary tangles (NFT), which are accompanied by more evident 
neuron death. The main component of SP is the beta amyloid peptide 
(Masters et al., 1985) whereas tau protein, in its phosphorylated form, 
is the main constituent of NFT (Grundke-Iqbal et al., 1986a,b).
The development of a tau pathology in AD correlates with the 
neurodegeneration  found  during  the  progression  of  the  disease 
(Braak and Braak, 1991), which also correlates with the appearance Frontiers in Neuroscience  | Neurodegeneration    June 2010  | Volume 4  | Article 49  |  2
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aggregation of intracellular tau (Frost et al., 2009). In this process, 
it is not known if the tau aggregates enter the cells by endocytosis 
or by another mechanism (Frost et al., 2009).
In a similar study in vivo (Clavaguera et al., 2009), the injection 
of a brain extract containing tau aggregates provoked the transmis-
sion and spreading of the tau pathology in a transgenic mouse that 
overexpresses human tau with a mutation (P301S) that is found in 
some patients with frontotemporal dementia (another tauopathy). 
Again, little is known about the possible mechanism underlying the 
spreading of tau from cell to cell, although in this case the influ-
ence of monomeric tau cannot be excluded since the brain extract 
used in the experiments could have contained both monomeric 
and aggregated tau.
A summary of the possible role of intracellular and extracellular 
tau is shown in Figure 1.
tau as a target
It is known that tau-deficient mice produced by gene targeting are 
viable (Harada et al., 1994; Dawson et al., 2001) and can reproduce, 
probably since some tau functions can be compensated for by other 
proteins, such as its role on microtubule dynamics. Accordingly, it 
is possible to consider the tau protein as a suitable target for the 
There is more data available about the toxicity of phosphor-
ylated intracellular tau and it has been suggested that phosphotau 
can sequester some other brain MAPs, producing a disorganiza-
tion of the microtubule network that might be toxic to a neuron 
(Alonso et al., 1997; Alonso Adel et al., 2006). Indeed, phosphotau 
appears to be toxic to neurons in a Drosophila model (Steinhilb 
et al., 2007; Feuillette et al., 2010), and inhibition of tau phos-
phorylation by altering GSK3 activity is correlated with reduced 
degeneration in vivo (Noble et al., 2005; Gomez de Barreda et al., 
2010b). Moreover, phosphorylated tau impairs learning in aged 
mice expressing human tau (Kimura et al., 2007).
Toxicity in neurons has also been related with conformational 
changes in the tau protein (Garcia-Sierra et al., 2008), which could 
provoke the appearance of aggregated truncated tau (Park and 
Ferreira, 2005; Zilka et al., 2009). However, the toxicity of aggregated 
tau still remains under debate (Duff and Planel, 2005), since neurons 
may live for decades with NFT in humans (Morsch et al., 1999). Also, 
in hibernating squirrels, tau accumulates in the somato-dendritic 
compartment and becomes hyperphosphorylated without causing 
neuronal cell death (Arendt et al., 2003). Thus it has been suggested 
that phosphorylation at specific sites, but not at others, could be 
needed for the toxic effect of tau (Alonso et al., 2008).
extracellular tau
The addition of recombinant tau protein to cultured neuronal cells 
produces an increase in intracellular calcium that could lead to neu-
ron degeneration (Gomez-Ramos et al., 2006). As indicated above, 
it has been suggested that endogenous intracellular tau may be 
released to the extracellular space upon neuron degeneration, where 
it could be toxic to other neurons (Gomez-Ramos et al., 2006). The 
concentration of Tau in a neuron is about 2 μM (Gamblin et al., 
2003; Reynolds et al., 2005) and concentrations as low as 35 pM 
of extracellular tau might produce an increase in the intracellular 
calcium concentration in neurons (Gomez-Ramos et al., 2009).
Although, it has been postulated that the presence of tau in 
the extracellular milieu is due to neuron degeneration, and that 
it can then be found in the cerebrospinal fluid (Iqbal et al., 2005), 
the presence of extracellular tau could be due to other causes. For 
example, it cannot be ruled out that tau might be exocytosed by 
cells, as indicated for the prion protein (Fevrier et al., 2004). Indeed, 
intraneuronal transfer of tau protein between neurons in situ has 
been recently described, suggesting that N-terminal region of tau 
is required for tau secretion (Kim et al., 2010).
The increase in intracellular calcium induced by Tau is caused by 
its interaction with specific cell receptors on neurons. After study-
ing the different possible mechanisms for the calcium mobilization 
provoked by tau, it was found to promote an increase in intracel-
lular calcium through its interaction with the M1 and M3 mus-
carinic receptors expressed by neurons (Gomez-Ramos et al., 2008). 
Monomeric tau interacts with cell receptors with a higher affinity 
than aggregated tau (Gomez-Ramos et al., 2006), and unmodified 
tau more readily than phosphorylated tau (Gomez-Ramos et al., 
2006). However, the tau present in the filaments that make up NFT 
is both phosphorylated and aggregated.
Nevertheless, using a fraction of enriched aggregated tau protein 
it was found that tau aggregates can enter cells of neuronal origin 
(Frost et al., 2009) and that exogenous aggregated tau induces the 
Figure 1 | (A) Intracellular tau is mainly bound to microtubules (MT) in the 
cytoplasm of a neuron but if it is phosphorylated (drawing with dots), its 
binding to MT decreases, and (B) it could also change its conformation and 
aggregate into filaments. (C) In its extracellular form, tau could exist as 
monomers or in filaments (aggregated form), and it could interact 
with neurons.www.frontiersin.org  June 2010  | Volume 4  | Article 49  |  3
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